SOPHiA GENETICS is a Swiss-headquartered, cloud-native healthcare software company that uses artificial intelligence to analyze multimodal data, including genomics and clinical information, to support oncology and rare-disease diagnostics. Its core offering, the SOPHiA DDM platform, is used by hundreds of hospitals, laboratories, and biopharmaceutical companies worldwide. The company generates recurring, usage-based revenue each time its platform analyzes a sample, giving the business a software-like model with a reported gross margin in the high-60% range.
Shares trade near $8, well above their 52-week low of about $3.15 and just under their 52-week high near $8.98. The stock has climbed significantly over the past year, supported by strong quarterly results. In its most recent quarter, the company reported roughly 27% year-over-year revenue growth, including 60% volume growth in the United States and 80% revenue growth in its liquid-biopsy segment. Management subsequently raised its full-year revenue outlook to a range of $94 million to $96 million, above prior consensus expectations.
A $10 price target matters for two reasons. First, it is a round, psychological number that investors tend to track closely. Second, it aligns closely with Wall Street's consensus analyst price target, which currently sits near $9.75 to $10. Because the stock has not yet traded above $10, the level represents both a fresh round-number milestone and a breakout above its prior 52-week high. That combination makes $10 the most widely watched objective in current market discussion.
Several factors support a path toward $10. The company's companion-diagnostics work, including partnerships linked to AstraZeneca, expands its presence in precision oncology. A joint venture with a major cancer center and growing adoption of its platform across U.S. health systems point to a larger installed base. Analysts at H.C. Wainwright have pointed to an estimated $40 billion addressable market and a recurring, usage-based revenue model as key differentiators. Continued revenue growth above 20%, improving margins, and a shrinking adjusted EBITDA loss would strengthen the bull case.
The primary obstacle is profitability. SOPHiA GENETICS remains deeply unprofitable, with a negative net margin and negative earnings per share (EPS), a measure of profit allocated to each share. The company has funded itself partly through equity offerings, which dilute existing shareholders, and insiders have sold shares under pre-arranged plans. The stock also carries a premium valuation, with analysts' models implying a forward price-to-earnings (P/E) ratio near 97 times, which leaves little room for execution missteps. Any slowdown in adoption, weaker-than-expected growth, or further dilution could delay a move toward $10.
Sell-side views are constructive but wide-ranging. The consensus rating is generally described as a Strong Buy, with an average analyst price target near $9.75 to $10. Individual targets vary sharply, from $7 at the low end to $14 at the high end. BTIG has raised its target to $9, while H.C. Wainwright has lifted its target to $14. The spread reflects genuine disagreement about how quickly the company can scale toward profitability, meaning $10 sits squarely in the middle of the analyst range rather than at its extremes.
From a technical analysis perspective, the $8.98 area, the prior 52-week high, is the first important resistance level. A decisive close above that zone would clear the way toward the $10 round-number objective. On the downside, support appears near the $7 area, with longer-term support reflected by the 200-day moving average around $5.71. The stock's longer-term trend structure has turned upward, but $10 will not be reached without first converting the prior high from resistance into support.
Traders monitoring SOPH and similar names can use Tickeron's AI Daily Buy/Sell Signals to track shifting conditions. The product applies artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. These signals can help traders discover new opportunities, monitor existing positions, and identify evolving market trends more efficiently than manual screening. For investors watching whether SOPH can reach $10, these AI-generated signals offer an additional data point for tracking momentum and trend changes.
A move to $10 appears realistic but not guaranteed. The company's accelerating growth, raised guidance, and expanding partnerships provide a credible foundation, and $10 aligns closely with the analyst consensus. However, persistent losses, a high valuation, and dilution risk are meaningful headwinds. Investors should monitor revenue growth rates, progress toward profitability, the sustainability of U.S. adoption, and whether shares can hold above the $8.98 prior high. Without sustained execution, the $10 level may remain just out of reach; with it, the target becomes a plausible near-to-medium-term objective.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that SOPH and TEM have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SOPH and TEM's prices will move in lockstep.
| Ticker / NAME | Correlation To SOPH | 1D Price Change % | ||
|---|---|---|---|---|
| SOPH | 100% | -4.18% | ||
| TEM - SOPH | 33% Poorly correlated | -6.59% | ||
| RIOT - SOPH | 32% Poorly correlated | -2.68% | ||
| COIN - SOPH | 30% Poorly correlated | +1.54% | ||
| MNDR - SOPH | 29% Poorly correlated | -4.51% | ||
| PSFE - SOPH | 28% Poorly correlated | -3.37% | ||
More | ||||
| Ticker / NAME | Correlation To SOPH | 1D Price Change % |
|---|---|---|
| SOPH | 100% | -4.18% |
| Services to the Health Industry industry (42 stocks) | 24% Poorly correlated | +2.69% |
| Health Services industry (241 stocks) | 2% Poorly correlated | +0.71% |